FIELD: chemistry.
SUBSTANCE: invention relates to biotechnology and is a peptide which induces killer T cells ex vivo and which has an amino acid sequence as shown in one SEQ ID NOS: from 1 to 3. The disclosed peptide is used in an ex vivo agent for inducing anti-tumour immunity, in an ex vivo agent for inducing antigen-presenting cells, in an ex vivo agent which induces tumour-reactive T cells, as well as in an ex vivo pharmaceutical agent when treating or preventing tumours. The invention also relates to an antibody against the said peptide.
EFFECT: disclosed agents enable identification of glypican-3-derivative peptide, which can bond with HLA-A2, and activation of human killer T cells in order to provide an immunotherapy agent which may be effective in approximately 40% Japanese patients suffering from certain types of malignant tumours, accompanied by high level of GPC3 expression.
7 cl, 4 dwg, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FOXM1 PEPTIDE AND MEDICINAL AGENT CONTAINING SAID PEPTIDE | 2008 |
|
RU2487886C2 |
| CDCA1 PEPTIDE AND PHARMACEUTICAL DRUG CONTAINING IT | 2008 |
|
RU2486195C2 |
| SPARC-DERIVATIVE ANTIGENIC PEPTIDES CAUSING TUMOUR REJECTION AND MEDICATIONS CONTAINING SUCH PEPTIDES | 2007 |
|
RU2451521C2 |
| PEPTIDE OBTAINED FROM GPC3, PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER USING IT, IMMUNITY INDUCER AND METHOD FOR PRODUCING ANTIGEN-PRESENTING CELLS | 2016 |
|
RU2714117C2 |
| TOPK PEPTIDES AND THEIR VACCINES | 2012 |
|
RU2633503C2 |
| EPITOPIC PEPTIDES RAB6KIFL/KIF20A AND VACCINES CONTAINING THEM | 2009 |
|
RU2532105C2 |
| UBE2T PEPTIDE AND VACCINES CONTAINING THE SAME | 2013 |
|
RU2663350C2 |
| CDH3-PEPTIDE AND DRUG PREPARATION CONTAINING IT | 2008 |
|
RU2483078C2 |
| KNTC2 PEPTIDES AND VACCINES CONTAINING THE SAME | 2014 |
|
RU2671395C2 |
| URLC10-DERIVED PEPTIDE AND VACCINE CONTAINING SAME | 2015 |
|
RU2700881C2 |
